• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Michael Hall wins Charles Rodolphe Brupbacher Prize for Cancer Research 2019

Bioengineer by Bioengineer
December 6, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Matthew Lee, Biozentrum


The prize worth 100,000 Swiss francs, established by Frédérique Brupbacher in memory of her husband Charles Rodolphe Brupbacher, will be awarded for the 14th time in January 2019, and is one of the most renowned awards for scientists working in cancer research world-wide. In 2019 the award will be presented to Michael Hall, Professor of Biochemistry at the University of Basel’s Biozentrum, for his fundamental discovery of the basic mechanism of cell growth control and how this contributes to cancer development.

Central control of cell growth discovered

In the early 1990s, while working at the Biozentrum in Basel, Michael Hall discovered the protein TOR (Target of Rapamycin). Using yeast as a simple model organism, Hall found that the TOR kinase is a central controller of cell growth and metabolism. The TOR enzyme is also found in all higher organisms, from worms and plants to mammals, in which it is known as mTOR. TOR forms two different multi-protein complexes, which function via a complicated network of signalling pathways. If the TOR signalling pathways are normally activated, the cell turns on its growth machinery and suppresses catabolic processes. In some cancers, TOR is abnormally activated.

Basis for targeted cancer treatment

Rapamycin is secreted by a soil bacterium and was initially found to inhibit fungal growth. After this first discovery, TOR was also found to act as an immunosuppressant and as well to block tumor growth. Michael Hall was able to show that faulty regulation of the mTOR signalling pathways is implicated in diseases such as cancer, diabetes and cardiovascular disease. Today, rapamycin and its derivatives are used to prevent organ rejection in transplant patients and to treat cancer. mTOR inhibitors have been used successfully for many years in the treatment of different types of cancer including kidney, pancreas, breast, stomach and lung. Indeed, the life expectancy of some patients with advanced cancer has been shown to be significantly extended by mTOR inhibitors.

###

Media Contact
Georg C. Umbricht
[email protected]
41-442-269-960

Original Source

https://www.media.uzh.ch/en/Press-Releases/2018/brupbacher-prize.html

News source: https://scienmag.com/

Tags: BiologycancerCell BiologyMedicine/HealthMolecular Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

Magnesium Implants Boost Bone-Immune Health In Vitro

Magnesium Implants Boost Bone-Immune Health In Vitro

August 2, 2025
GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

August 2, 2025

Deep Learning Advances MRI Diagnosis of Brucella

August 2, 2025

Predicting Lung Infections After Brain Hemorrhage

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    43 shares
    Share 17 Tweet 11
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lorlatinib’s Real-World Impact on ALK+ NSCLC

TrueBeam vs. Halcyon: Breast Cancer Radiotherapy Comparison

Magnesium Implants Boost Bone-Immune Health In Vitro

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.